Feature | April 08, 2014| Dave Fornell

CRT-D Therapy Improves Long-term Survival in Heart Failure Patients Over ICD

Study finds clear benefits of CRT-D in MADIT-CRT long-term follow up

ICD, MADIT-CRT trial, long-term followup, ACC.14
Patients in mild heart failure who receive a cardiac resynchronization therapy defibrillator (CRT-D) device may live longer than those implanted with a traditional implantable cardioverter defibrillator (ICD), according to research presented at the American College of Cardiology’s 63rd Annual Scientific Session.
In the longest follow-up of CRT for patients with mild heart failure to date, the continued analysis of the landmark MADIT-CRT study showed heart failure patients with left bundle branch block (LBBB) implanted with a CRT-D had a 41 percent reduced risk of death compared to patients who had a conventional ICD. The probability of all-cause mortality at seven years was 18 percent among the CRT-D patients, compared to 29 percent in the ICD group in this subset of patients. The five-year survival rate for patients with CRT-D was close to 90 percent, and more than 80 percent of patients who received CRT therapy were still alive at seven years. 
In addition to the mortality benefit, the results demonstrate that these patients experienced a 62 percent relative reduction in the risk of experiencing a first heart failure event when compared to patients who did not receive CRT therapy.
“Based on our findings, we now have an intervention that can potentially change the outcomes for certain heart failure patients,” said Ilan Goldenberg, M.D., director of the department of cardiology, Israel’s Leviev Heart Center, Sheba Medical Center, Tel Hashomer, Israel, and one of the lead investigators of the study. “We can intervene early in the course of the disease to reduce the risk of long-term mortality in these patients.”
The MADIT-CRT trial was originally conducted to expand the FDA indications for CRT-D use in mild heart failure patients to prevent them from progressing from New York Heart Assn. Class I or II heart failure to advanced stage Class III or IV. 
Trial Details 
The Multicenter Automatic Defibrillator Implantation with Cardiac Resynchronization Therapy (MADIT-CRT) trial enrolled 1,820 patients with mild or no heart failure symptoms — including 1,281 with LBBB in this analysis — and randomized them to receive CRT-D therapy or ICD. ICDs are implanted in the right ventricle of patients at high risk of sudden cardiac death due to heart arrhythmias. When patients have a life-threatening arrhythmia, the ICD delivers an electrical shock to help restore a regular heartbeat. A CRT-D differs from an ICD in that it has a second electrode over the left ventricle of the heart to help synchronize a patient’s heartbeat and improve cardiac function.
Patients enrolled in the study were diagnosed with New York Heart Assn. Class I or II (mild) heart failure, left ventricular dysfunction and an ejection fraction of 30 percent or lower. The original trial followed patients for an average of 2.4 years, and the current study extended this follow-up for up to seven years from enrollment.
According to Goldenberg, previous studies have shown survival benefits from CRT-D in patients with moderate-to-severe symptoms, where intervention took place relatively late in the course of the disease when mortality rates are high. This study is the first to show the significant survival benefit when CRT-D is used with mildly symptomatic patients or asymptomatic patients with cardiac dysfunction.
The significant long-term survival benefit of CRT-D in the trial was observed only among patients with LBBB, Goldenberg said. The study does not support early intervention with CRT-D in patients without LBBB. 
While researchers expected to find mortality reduction in patients with left bundle branch block during long-term follow-up. “We were surprised by the consistency of results in each subgroup of these patients, regardless of age, gender or the cause or duration of heart failure,” Goldenberg said.
Goldenberg recommends additional research to see if similar benefits are found in patients with higher ejection fractions and among those without any symptoms of heart failure. The study was supported by an unrestricted grant from Boston Scientific, St. Paul, Minn.
CRT Battery Life Extended
One issue with implantable electrophysiology devices has been battery life, which has become more of an issue as survival continues to improve due to these devices. Boston Scientific, the sponsor of the MADIT-CRT trial, said the new battery technology in its CRT-Ds has lasted in this trial out to at least seven years. The vendor said longer battery life may reduce the need for additional device implants in patients with heart failure, and could help reduce healthcare costs.
This study was simultaneously published online in the New England Journal of Medicine at the time of presentation.

Related Content

Acutus Medical, AcQMap High Resolution Imaging and Mapping System, improvement over sCT

Image courtesy of Acutus Medical

News | EP Mapping and Imaging Systems| October 06, 2015
Acutus Medical, a global heart rhythm technology company, presented data that show the AcQMap High Resolution Imaging...
Aortix device, TCT, Interventional Innovation Shark Tank Competition, catheter-based circulatory heart pump

Image courtesy of Procyrion

News | Ventricular Assist Devices (VAD)| October 06, 2015
The novel Aortix device has earned a spot among the diagnostic and therapeutic modalities accepted for presentation in...
Procyrion, Aortix device, grand prize, Create the Future Design Contest

Aortix device image courtesy of Procyrion Inc.

News | Ventricular Assist Devices (VAD)| October 05, 2015
Procyrion Inc. of Houston has been awarded the grand prize of $20,000 in the 2015 "Create the Future" Design Contest...
News | Heart Failure| October 02, 2015
Cyberonics Inc. announced results from the extension of the ANTHEM-HF clinical study (ENCORE Study). Results of the...
Tryton Side Branch Stent, clinical trial results, Catheterization and Cardiovascular Interventions

Tryton Side Branch Stent image courtesy of Tryton Medical

News | Stents Bifurcation| October 02, 2015
October 2, 2015 — Tryton Medical Inc.
AtriCure, cryoFORM cryoablation probe, launch
Technology | Ablation Systems| October 02, 2015
AtriCure Inc. launched the cryoFORM cryoablation probe, which offers increased probe flexibility to adapt to a variety...
Intact Vascular, TOBA II study, Tack Endovascular System

Image courtesy of Intact Vascular

News | Peripheral Arterial Disease (PAD)| October 01, 2015
Intact Vascular Inc. announced the U.S. Food and Drug Administration has granted conditional approval for a U.S. and...
Johns Hopkins, sticky gel, stem cells, rat hearts, heart attacks

Hydrogel applied to beating rat hearts improves stem cell uptake by the heart muscle and speeds up tissue healing after heart attack. Image courtesy of Johns Hopkins Medicine.

News | Stem Cell Therapies| September 29, 2015
A sticky, protein-rich gel created by Johns Hopkins researchers appears to help stem cells stay on or in rat hearts and...
American Heart Association, AHA, heart failure, HF, Rise Above Heart Failure initiative, report
News | Heart Failure| September 29, 2015
September 29, 2015 — A new report from the American Heart Association (AHA) projects that the number of Americans dia
News | Cath Lab| September 29, 2015
The Innovation Institute announced that Boston Scientific has signed an agreement to become the founding medical device...
Overlay Init